Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers

NCT05188469 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

67

Enrollment

OTHER

Sponsor class

Conditions

COVID-19 Vaccine

Interventions

DRUG: EG-COVID-003
DRUG: EG-COVID-001
DRUG: A: EG-COVID
DRUG: B: EG-COVID
DRUG: C: EG-COVARo

Sponsor

EyeGene Inc.

Collaborators

[object Object]